PARKING REQUEST FORM » | MAP & DIRECTIONS » |
|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 354
|
ARB 355
|
Link to Teams Meeting
|
|||||
SESSION 1
1:00 – 1:45 pm
|
Sidney D'Amico, Pharm.D.
Use of Rifaximin in Hepatic Encephalopathy Prevention and Treatment
|
Kristin Hoff, Pharm.D.
Treatment Options in 2021 for Multidrug Resistant Acinetobacter
|
Ryan Moran, Pharm.D.
Gasping to Grasp Relief Inhalers in Asthma: ICS/Formoterol vs. Albuterol
|
Hanna Teer, Pharm.D.
Treatment Recommendations for Transthyretin Cardiac Amyloidosis
|
Diana Barajas, Pharm.D.
Use of DOACs for VTE Prophylaxis in Ambulatory Cancer Patients
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
||||
SESSION 2
1:55 – 2:40
|
Elizabeth Eastman, Pharm.D.
Myxedema Coma: Considerations for Thyroid Hormone Replacement
|
Lauren Hetzler, Pharm.D.
Antibiotic De-Escalation in Febrile Neutropenia
|
Ulyana Kucherepa, Pharm.D.
Extended Venous Thromboembolism Prophylaxis Beyond Hospitalization in Medically ill Patients
|
Beverly Anderson, Pharm.D.
Pharmacologic Strategies for Diuretic Resistance in Acute Decompensated Heart Failure
|
Ashley Lopez, Pharm.D.
Expanded Role of Rivaroxaban in Patients with Diabetes and Coronary Artery Disease
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
||||
SESSION 3
2:50 – 3:40 pm
|
Maria Gorla, Pharm.D.
Enteral Feeding in Critically Ill Patients
|
Molly Jorns, Pharm.D.
Oral Antibiotics for Step-down Therapy in Uncomplicated Gram-Negative Bacteremia
|
Leanne Allas, Pharm.D.
Two's Company, Three's a Crowd: Optimizing Therapy for People Living with HIV
|
Jesse Smith, Pharm.D.
Beta Blockade in Sepsis
|
Valerie Yuenger, Pharm.D.
Direct-Acting Oral Anticoagulants for the Treatment of Left Ventricular Thrombus
|
Click here for a printable copy of the schedule
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, December 10, 2021 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Dec 16, 2021 01:00 PM - 03:40 PM
Fee
CE Hours
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Objectives
- Evaluate the benefit of rifaximin use in the treatment of hepatic encephalopathy
- Identify patients who would benefit from rifaximin in the prevention of hepatic encephalopathy
Speaker(s)/Author(s)
Sidney D'Amico, Pharm.D. |
Activity Number
0033-0000-21-074-L01-PCE Hours
Location
Objectives
- Identify current treatment options for carbapenem resistant Acinetobacter infections
- Summarize the current data behind eravacycline and cefiderocol for the treatment of Acinetobacter infection
- Identify place in therapy for new antimicrobial agents for the treatment of multidrug resistant Acinetobacter infection
Speaker(s)/Author(s)
Kristin Hoff, Pharm.D. |
Activity Number
0033-0000-21-064-L01-PCE Hours
Location
Objectives
- Identify a preferred relief inhaler for patients with asthma according to the most recent GINA guidelines
- Summarize the data supporting ICS/formoterol as the preferred relief inhaler in the most recent GINA guidelines
Speaker(s)/Author(s)
Ryan Moran, Pharm.D. |
Activity Number
0033-0000-21-067-L01-PCE Hours
Location
Objectives
- Define cardiac amyloidosis
- Identify patients at risk for cardiac amyloidosis
- Describe appropriate strategies for diagnosing and treating cardiac amyloidosisDetermine what agent is the most appropriate treatment regimen for a patient with cardiac amyloidosis
- Determine what agent is the most appropriate treatment regimen for a patient with cardiac amyloidosis
Speaker(s)/Author(s)
Hanna Teer, Pharm.D. |
Activity Number
0033-0000-21-077-L01-PCE Hours
Location
Objectives
- Identify specific risk factors in ambulatory patients with active malignancy that increase the risk of developing cancer-associated venous thromboembolism
- Describe current literature that supports the use of direct oral anticoagulants as thromboprophylaxis options for ambulatory patients with active malignancy
- Explain limitations of the use of direct oral anticoagulants for thromboprophylaxis in ambulatory patients with active malignancy
Speaker(s)/Author(s)
Diana Barajas, Pharm.D. |
Activity Number
0033-0000-21-063-L01-pCE Hours
Location
Objectives
- Describe the clinical presentation of a patient with myxedema coma
- Identify the components of a treatment regimen for a patient with myxedema coma
- Summarize the data available regarding the use of thyroid hormones in the treatment patients with myxedema coma
Speaker(s)/Author(s)
Elizabeth Eastman, Pharm.D. |
Activity Number
0033-0000-21-070-L01-PCE Hours
Location
Objectives
- Describe the conventional approach to treating febrile neutropenia
- Compare the three current guidelines for febrile neutropenia
- Summarize the evidence for de-escalating to fluoroquinolone prophylaxis in febrile neutropenia before neutrophil recovery
Speaker(s)/Author(s)
Lauren Hetzler, Pharm.D. |
Activity Number
0033-0000-21-071-L01-PCE Hours
Location
Objectives
- Discuss major venous thromboembolism risk stratifications tools
- Discuss major clinical trials representing the efficacy and safety associated with the use of extended venous thromboembolism prophylaxis in medically-ill patients beyond hospitalization
- Select patients who might qualify for extended venous thromboembolism prophylaxis beyond hospitalization
Speaker(s)/Author(s)
Ulyana Kucherepa, Pharm.D. |
Activity Number
0033-0000-21-065-L01-PCE Hours
Location
Objectives
- Describe the possible mechanisms of diuretic resistance
- Compare and contrast the efficacy and safety of thiazide diuretics and arginine vasopressin (AVP) antagonists
- Select an appropriate treatment regimen for a patient with acute decompensated heart failure (ADHF) with diuretic resistance
Speaker(s)/Author(s)
Beverly Anderson, Pharm.D. |
Activity Number
0033-0000-21-075-L01-PCE Hours
Location
Objectives
- Compare and contrast the efficacy and safety outcomes associated with the addition of low dose rivaroxaban to aspirin in patients with diabetes and stable coronary artery disease
- Summarize the mechanism contributing to the increased thrombotic environment in patients with diabetes
- Identify patients that would potentially benefit from dual pathway inhibition therapy with low dose rivaroxaban plus aspirin
Speaker(s)/Author(s)
Ashley Lopez, Pharm.D. |
Activity Number
0033-0000-21-066-L01-PCE Hours
Location
Objectives
- Describe why enteral nutrition was historically avoided in critically ill patients
- Identify which vasopressors impact the use of enteral nutrition in critically ill patients
- Distinguish patients who may be candidates for early enteral nutrition
Speaker(s)/Author(s)
Maria Gorla, Pharm.D. |
Activity Number
0033-0000-21-073-L01-PCE Hours
Location
Objectives
- Identify common pathogens associated with gram-negative bacteremia
- Distinguish between high, moderate, and low bioavailability antibiotics
- Select patients who are candidates for oral antibiotic step-down therapy in uncomplicated gram-negative bacteremia
Speaker(s)/Author(s)
Molly Jorns, Pharm.D. |
Activity Number
0033-0000-21-068-L01-PCE Hours
Location
Objectives
- Identify when the switch from a traditional 3 drug antiretroviral therapy to 2 drug antiretroviral therapy is appropriate
- Compare the use of 2 drug antiretroviral therapy regimens to the traditional 3 drug antiretroviral therapy regimens to optimize treatment for persons living with HIV
Speaker(s)/Author(s)
Leanne Allas, Pharm.D. |
Activity Number
0033-0000-21-069-L01-PCE Hours
Location
Objectives
- Describe the mechanisms in which sepsis can induce cardiac dysfunction
- Summarize recent literature evaluating beta-blocker therapy in patients with sepsis
- Identify patient specific characteristics that may see the most benefit or harm from starting beta-blocker therapy in sepsis
Speaker(s)/Author(s)
Jesse Smith, Pharm.D. |
Activity Number
0033-0000-21-076-L01-PCE Hours
Location
Objectives
- Summarize existing literature for the use of DOACs for the treatment of LVT
- Identify the role of DOACs for the treatment of LVT
Speaker(s)/Author(s)
Valerie Yuenger, Pharm.D. |